Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
25 Octobre 2023 - 2:30PM
via NewMediaWire – Aclarion, Inc.,
(“Aclarion” or the
“Company”) (Nasdaq: ACON, ACONW), a healthcare technology
company that is leveraging biomarkers and proprietary augmented
intelligence algorithms to help physicians identify the location of
chronic low back pain, announced today their expanded footprint in
Colorado with AdventHealth Porter. From their location in
Denver, AdventHealth Porter provides exceptional medical care to
patients throughout the front range of Colorado.
George Frey MD, Orthopedic Surgeon and founder of the Colorado
Comprehensive Spine Institute said, “Treating patients effectively
starts with an informed understanding of where their pain is coming
from. In my experience with Nociscan, objectively measuring the
biomarker content corelated with pain within a disc that may look
healthy on an MRI, adds to my knowledge of how to treat that
patient. At AdventHealth Porter, we are committed to provide
the highest quality cost effective care possible. The published
evidence is clear to me that adding Nociscan to our diagnostic
evaluation may help us do that.”
Brent Ness, CEO of Aclarion, said, “In keeping with our strategy
to drive Nociscan to standard of care through KOL advocacy, we
applaud AdventHealth Porter in bringing Nociscan technology to
Denver in support of Dr. Frey’s vision to utilize our technology to
improve outcomes while lowering costs. The support of pioneering
leaders like Dr. Frey and AdventHealth is exactly the leadership we
need to unequivocally demonstrate the superior clinical outcomes
for patients that will drive coverage decisions by payers and give
all patients access to Nociscan technology. We thank Dr. Frey and
AdventHealth and look forward to the positive impact increasing
Nociscan volumes will have on the surgical outcomes of chronic low
back patients in and around the Denver community.”
“Providing exceptional care with leading-edge treatments is a
core value of our multidiscipline healthcare team here at
AdventHealth Porter,” stated Carol Bermingham, Imaging Manager at
AdventHealth Porter. “We are enthusiastic about adding Nociscan to
our MRI capability and believe providing personalized biomarker
data to treating physicians is yet another investment in our
commitment to providing an environment where our doctors can do
their very best for their patients. Our radiology service line is
always striving to stay on the front edge of the technical
advancement curve.”
Chronic low back pain (cLBP) is a global healthcare problem,
with approximately 266 million people worldwide suffering from
degenerative spine disease and low back pain. Low back pain has
been estimated to affect up to 30 million adults in the US
population each year, leading to millions of physician consults per
year.
Aclarion’s proprietary decision-support tool, Nociscan, is the
first evidence-supported SaaS platform to noninvasively help
physicians distinguish between painful and nonpainful discs in the
lumbar spine. Nociscan objectively quantifies chemical biomarkers
demonstrated to be associated with disc pain. Biomarker data is
entered into proprietary algorithms to highlight if a disc may be a
source of pain. When used with other diagnostic tools, Nociscan
provides critical insights into the location of a patient’s low
back pain, giving physicians clarity to optimize treatment
strategies. About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages
Magnetic Resonance Spectroscopy (“MRS”), proprietary signal
processing techniques, biomarkers, and augmented intelligence
algorithms to optimize clinical treatments. The Company is first
addressing the chronic low back pain market with Nociscan, the
first, evidence-supported, SaaS platform to noninvasively help
physicians distinguish between painful and nonpainful discs in the
lumbar spine. Through a cloud connection, Nociscan receives
magnetic resonance spectroscopy (MRS) data from an MRI machine for
each lumbar disc being evaluated. In the cloud, proprietary signal
processing techniques extract and quantify chemical biomarkers
demonstrated to be associated with disc pain. Biomarker data is
entered into proprietary algorithms to indicate if a disc may be a
source of pain. When used with other diagnostic tools, Nociscan
provides critical insights into the location of a patient’s low
back pain, giving physicians clarity to optimize treatment
strategies. For more information, please visit
www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 about the Company's current
expectations about future results, performance, prospects and
opportunities. Statements that are not historical facts, such as
"anticipates," "believes" and "expects" or similar expressions, are
forward-looking statements. These forward-looking statements are
based on the current plans and expectations of management and are
subject to a number of uncertainties and risks that could
significantly affect the Company's current plans and expectations,
as well as future results of operations and financial condition.
These and other risks and uncertainties are discussed more fully in
our filings with the Securities and Exchange Commission. Readers
are encouraged to review the section titled "Risk Factors" in the
Company's Prospectus dated April 21, 2022, as filed with the
Securities and Exchange Commission on April 25, 2022 under Rule
424(b)(4), as well as other disclosures contained in the Prospectus
and subsequent filings made with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date and the Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contacts:Kirin M. SmithPCG Advisory,
Inc.646.823.8656ksmith@pcgadvisory.com
Media Contacts:Jodi LambertiSPRIG
Consulting612.812.7477jodi@sprigconsulting.com
Aclarion (NASDAQ:ACONW)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Aclarion (NASDAQ:ACONW)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024